We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Cryo-Save | LSE:CRYO | London | Ordinary Share | NL0009272137 | ORD EUR0.10 (DI) |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 420.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
TIDMCRYO
RNS Number : 9863K
Cryo-Save Group NV
29 April 2010
29 April 2010
Cryo-Save Group N.V.
Grant of share options
Cryo-Save Group N.V. (AIM/Euronext: CRYO, 'Cryo-Save' or 'the Group'), Europe's
leading stem cell bank, announces that on 28 April 2010 the Group granted
options to subscribe for ordinary shares in the Company under the Cryo-Save
Group 2009 Share Option Scheme.
The Company granted 20,000 options to Arnoud van Tulder, Chief Financial
Officer, and 34,000 options to certain other employees of the Group all at an
exercise price of EUR5.81 per share, being the price equal to the arithmetic
average of the closing mid-market price over the five dealing days prior to the
date of the grant. All of these options are exercisable at any time from 29
April 2013 until 29 April 2020.
The Company now has a total of 204,000 options over ordinary shares outstanding.
Enquiries:
+-------------------------------------+---------------------+
| Cryo-Save Group | + 31 (0)575 548998 |
+-------------------------------------+---------------------+
| Marc Waeterschoot, Chief Executive | |
+-------------------------------------+---------------------+
| Arnoud van Tulder, Chief Financial | |
| Officer | |
+-------------------------------------+---------------------+
| | |
+-------------------------------------+---------------------+
| Daniel Stewart & Company plc | + 44 (0)20 7776 |
| | 6550 |
+-------------------------------------+---------------------+
| Simon Leathers/Emma Earl | |
+-------------------------------------+---------------------+
| | |
+-------------------------------------+---------------------+
| College Hill (UK) | + 44 (0)20 7457 |
| | 2020 |
+-------------------------------------+---------------------+
| Adrian Duffield/Rozi Morris | |
+-------------------------------------+---------------------+
| | |
+-------------------------------------+---------------------+
| SPJ Financiële Communicatie | +31 (0)20 647 8181 |
| Amstelveen (NL) | |
+-------------------------------------+---------------------+
| Kees Jongsma/Léon Melens | |
+-------------------------------------+---------------------+
About Cryo-Save
With more than 120,000 samples saved, Cryo-Save is the leading stem cell bank in
Europe and one of the fastest growing in the world. Driven by its international
business strategy, Cryo-Save is now represented in 38 countries on three
continents and has state-of-the-art processing facilities in Belgium, Germany,
Dubai, India and France (under construction).
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCIPMATMBITBRM
1 Year Cryo-Save Chart |
1 Month Cryo-Save Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
